USA Bio-pharma Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Bio-pharma Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Monoclonal Antibodies Market Performance (Volume)
  • 2.1.2 Recombinant Proteins Market Performance (Volume)
  • 2.1.3 Granulocyte-Colony Stimulating Factor (G-CSF) Market Performance (Volume)
  • 2.1.4 Interferons Market Performance (Volume)
  • 2.1.5 Recombinant Human Insulin Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Monoclonal Antibodies Market Performance (Value)
  • 2.1.2 Recombinant Proteins Market Performance (Value)
  • 2.1.3 Granulocyte-Colony Stimulating Factor (G-CSF) Market Performance (Value)
  • 2.1.4 Interferons Market Performance (Value)
  • 2.1.5 Recombinant Human Insulin Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Metabolic Disorders Market Performance (Volume)
  • 3.1.2 Oncology Market Performance (Volume)
  • 3.1.3 Neurological Disorders Market Performance (Volume)
  • 3.1.4 Cardiovascular Diseases Market Performance (Volume)
  • 3.1.5 Inflammatory and Infectious Diseases Market Performance (Volume)
  • 3.1.6 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Pfizer
  • 4.1.1 Pfizer Profiles
  • 4.1.2 Pfizer Product Information
  • 4.1.3 Pfizer Bio-pharma Business Performance
  • 4.1.4 Pfizer Bio-pharma Business Development and Market Status
• 4.2 F. Hoffmann-La Roche AG
  • 4.2.1 F. Hoffmann-La Roche AG Profiles
  • 4.2.2 F. Hoffmann-La Roche AG Product Information
  • 4.2.3 F. Hoffmann-La Roche AG Bio-pharma Business Performance
  • 4.2.4 F. Hoffmann-La Roche AG Bio-pharma Business Development and Market Status
• 4.3 Johnson & Johnson Services
  • 4.3.1 Johnson & Johnson Services Profiles
  • 4.3.2 Johnson & Johnson Services Product Information
  • 4.3.3 Johnson & Johnson Services Bio-pharma Business Performance
  • 4.3.4 Johnson & Johnson Services Bio-pharma Business Development and Market Status
• 4.4 Sanofi, Amgen
  • 4.4.1 Sanofi, Amgen Profiles
  • 4.4.2 Sanofi, Amgen Product Information
  • 4.4.3 Sanofi, Amgen Bio-pharma Business Performance
  • 4.4.4 Sanofi, Amgen Bio-pharma Business Development and Market Status
• 4.5 AbbVie
  • 4.5.1 AbbVie Profiles
  • 4.5.2 AbbVie Product Information
  • 4.5.3 AbbVie Bio-pharma Business Performance
  • 4.5.4 AbbVie Bio-pharma Business Development and Market Status
• 4.6 Merck & Co., Inc
  • 4.6.1 Merck & Co., Inc Profiles
  • 4.6.2 Merck & Co., Inc Product Information
  • 4.6.3 Merck & Co., Inc Bio-pharma Business Performance
  • 4.6.4 Merck & Co., Inc Bio-pharma Business Development and Market Status
• 4.7 Biogen Idec
  • 4.7.1 Biogen Idec Profiles
  • 4.7.2 Biogen Idec Product Information
  • 4.7.3 Biogen Idec Bio-pharma Business Performance
  • 4.7.4 Biogen Idec Bio-pharma Business Development and Market Status
• 4.8 Bayer AG
  • 4.8.1 Bayer AG Profiles
  • 4.8.2 Bayer AG Product Information
  • 4.8.3 Bayer AG Bio-pharma Business Performance
  • 4.8.4 Bayer AG Bio-pharma Business Development and Market Status
• 4.9 Eli Lilly and Company
  • 4.9.1 Eli Lilly and Company Profiles
  • 4.9.2 Eli Lilly and Company Product Information
  • 4.9.3 Eli Lilly and Company Bio-pharma Business Performance
  • 4.9.4 Eli Lilly and Company Bio-pharma Business Development and Market Status
• 4.10 Novartis AG GlaxoSmithKline Plc
  • 4.10.1 Novartis AG GlaxoSmithKline Plc Profiles
  • 4.10.2 Novartis AG GlaxoSmithKline Plc Product Information
  • 4.10.3 Novartis AG GlaxoSmithKline Plc Bio-pharma Business Performance
  • 4.10.4 Novartis AG GlaxoSmithKline Plc Bio-pharma Business Development and Market Status
• 4.11 Bristol-Myers Squibb Company
• 4.12 AstraZeneca PLC
• 4.13 Johnson & Johnson Services

5 Market Performance for Manufacturers

• 5.1 USA Bio-pharma Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 USA Bio-pharma Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 USA Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 USA Bio-pharma Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Northeast Market Performance for Manufacturers
  • 6.1.1 Northeast Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Northeast Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Northeast Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Northeast Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Midwest Market Performance for Manufacturers
  • 6.2.1 Midwest Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Midwest Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Midwest Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Midwest Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Market Performance for Manufacturers
  • 6.3.1 South Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 West Market Performance for Manufacturers
  • 6.4.1 West Bio-pharma Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 West Bio-pharma Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 West Bio-pharma Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 West Bio-pharma Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration

7 USA Bio-pharma Market Performance (Sales Point)

• 7.1 USA Bio-pharma Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 USA Bio-pharma Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 USA Bio-pharma Price (USD/Unit) by Regions 2013-2018
• 7.4 USA Bio-pharma Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 USA Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Northeast Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Midwest Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 West Bio-pharma Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Metabolic Disorders Industry
• 11.2 Oncology Industry
• 11.3 Neurological Disorders Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 USA Bio-pharma Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 USA Bio-pharma Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Northeast Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Midwest Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 West Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Bio-pharma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Monoclonal Antibodies Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Recombinant Proteins Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Interferons Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Metabolic Disorders Sales and and Growth Rate 2019-2024
  • 12.4.3 Oncology Sales and and Growth Rate 2019-2024
  • 12.4.4 Neurological Disorders Sales and and Growth Rate 2019-2024
  • 12.4.5 Cardiovascular Diseases Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 USA Bio-pharma Price (USD/Unit) Trend 2019-2024
  • 12.5.2 USA Bio-pharma Gross Profit Trend 2019-2024

13 Conclusion